Results 11 to 20 of about 27,707 (119)

Rate of Homologous Desensitization and Internalization of the GLP-1 Receptor

Molecules, 2016
The glucagon-like peptide-1 receptor (GLP-1R) is an important target in the treatment of type 2 diabetes mellitus. The aim of this study was to compare the rate of agonist stimulated desensitization and internalization of GLP-1R.
Ghina Shaaban, Mabayoje Oriowo, Suleiman Al-Sabah   +2 more
doaj   +1 more source

Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. [PDF]

PLoS ONE, 2010
GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2168 h. Intraperitoneal glucose tolerance test (IPGTT) in mice showed that GLP-1/hIgG2 significantly decreased ...
Qinghua Wang, Kui Chen, Rui Liu, Fang Zhao, Sandeep Gupta, Nina Zhang, Gerald J Prud'homme   +6 more
doaj   +1 more source

Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA

BMJ Open Diabetes Research & Care, 2019
Introduction This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM ...
Mukul Singhal, Hiangkiat Tan, Craig I Coleman, Michelle Han, Chi Nguyen, Michael Ingham   +5 more
doaj   +1 more source

The first successful desensitization protocol in exenatide allergy: a case report

Allergy, Asthma & Clinical Immunology, 2023
Background Glucagon-like peptide-1 (GLP-1) receptor agonists are important treatment options in obese patients with type 2 diabetes. To date, few immediate allergic reactions due to GLP-1 receptor agonists were reported.
Osman Ozan Yeğit, Göktuğ Sarıbeyliler, Pelin Karadağ, Semra Demir, Nurdan Gül, Derya Ünal, Aslı Gelincik Akkor   +6 more
doaj   +1 more source

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury

Pharmaceuticals, 2022
Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a promising therapy for type 2 diabetes mellitus (T2DM). GLP-1 is an incretin hormone with therapeutic potential beyond type
Ali Ismaeil, Fawzi Babiker, Suleiman Al-Sabah   +2 more
doaj   +1 more source

Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway. [PDF]

PLoS ONE, 2017
Glucagon-like peptide-1 (GLP-1) receptor plays an essential role in regulating glucose metabolism. GLP-1 receptor agonists have been widely used for treating diabetes and other insulin resistance-related diseases.
Anping Wang, Ting Li, Ping An, Wenhua Yan, Hua Zheng, Baoan Wang, Yiming Mu   +6 more
doaj   +1 more source

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys

Cell Reports Medicine, 2021
Summary: Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) regulate glucose and energy homeostasis. Targeting both pathways with GIP receptor (GIPR) antagonist antibody (GIPR-Ab) and GLP-1 receptor (GLP-1R) agonist ...
Shu-Chen Lu, Michelle Chen, Larissa Atangan, Elizabeth A. Killion, Renee Komorowski, Yuan Cheng, Chawita Netirojjanakul, James R. Falsey, Marina Stolina, Denise Dwyer, Clarence Hale, Shanaka Stanislaus, Todd Hager, Veena A. Thomas, John M. Harrold, David J. Lloyd, Murielle M. Véniant   +16 more
doaj   +1 more source

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI Insight, 2020
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.
Francis S. Willard, Jonathan D. Douros, Maria B.N. Gabe, Aaron D. Showalter, David B. Wainscott, Todd M. Suter, Megan E. Capozzi, Wijnand J.C. van der Velden, Cynthia Stutsman, Guemalli R. Cardona, Shweta Urva, Paul J. Emmerson, Jens J. Holst, David A. D’Alessio, Matthew P. Coghlan, Mette M. Rosenkilde, Jonathan E. Campbell, Kyle W. Sloop   +17 more
doaj   +1 more source

Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD) [PDF]

Avicenna Journal of Medical Biochemistry, 2017
Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be 24%. At present no approved medicines are available for NAFLD treatment. Glucagon-like peptide-1 (GLP-1) is a significant regulator of
Ebrahim Abbasi Oshaghi
doaj   +1 more source

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Journal of Diabetes Investigation, 2019
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus.
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku   +7 more
doaj   +1 more source